Standard BioTools (NASDAQ:LAB - Get Free Report) will likely be releasing its Q1 2025 earnings data after the market closes on Tuesday, May 6th. Analysts expect the company to announce earnings of ($0.04) per share and revenue of $40.10 million for the quarter.
Standard BioTools Stock Performance
Shares of NASDAQ LAB traded up $0.09 during midday trading on Friday, reaching $1.20. The company's stock had a trading volume of 785,935 shares, compared to its average volume of 2,188,463. The business's 50 day moving average price is $1.14 and its two-hundred day moving average price is $1.54. Standard BioTools has a fifty-two week low of $0.97 and a fifty-two week high of $2.74. The company has a market cap of $454.78 million, a P/E ratio of -1.69 and a beta of 1.54.
Insider Activity at Standard BioTools
In related news, Director Casdin Partners Master Fund, L bought 4,820,959 shares of the company's stock in a transaction dated Friday, February 28th. The stock was purchased at an average price of $1.06 per share, with a total value of $5,110,216.54. Following the completion of the acquisition, the director now owns 58,846,780 shares of the company's stock, valued at $62,377,586.80. The trade was a 8.92 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 53.10% of the stock is currently owned by insiders.
Analyst Ratings Changes
Separately, KeyCorp downgraded Standard BioTools from an "overweight" rating to a "sector weight" rating in a research note on Thursday, February 27th.
Get Our Latest Stock Analysis on Standard BioTools
About Standard BioTools
(
Get Free Report)
Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.
Further Reading
Before you consider Standard BioTools, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Standard BioTools wasn't on the list.
While Standard BioTools currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
